Transporter-mediated drug interactions: clinical implications and in vitro assessment

Bibliography

• LIN JH, YAMAZAKI M: Role of P-glycoprotein in pharmacokinetics. Clinical implications. Clin. Pharmacokinet. (2003) 42(1):59-98.
   PubMed Web of Science ®Google Scholar
• LIN JH, YAMAZAKI M: Clinical relevance of P-glycoprotein in drug therapy. Drug Metab. Rev. (2003) 35(4):417-454.
   PubMed Web of Science ®Google Scholar
• KIM RB: Transporters and xenobiotic disposition. Toxicology (2002) 181-182:291-297.
   PubMed Web of Science ®Google Scholar
• ITO K, SUZUKI H, HORIE T et al.: Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. (2005) 22(10):1559-1577.
   PubMed Web of Science ®Google Scholar
• LIN JH, LU AYH: Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. (1998) 35(5):361-390.
   PubMed Web of Science ®Google Scholar
• LIN JH: CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm. Res. (2006) 23(6):1089-1116.
   PubMed Web of Science ®Google Scholar
• LIN JH: Drug–drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev. (2003) 55(1):53-81.
   PubMed Web of Science ®Google Scholar
• KOVARIK JM, RIGAUDY L, GUERRET M et al.: Longitudinal assessment of a P-glycoprotein-mediated interaction of valspodar on digoxin. Clin. Pharmacol. Ther. (1999) 66(4):391-400.
   PubMed Web of Science ®Google Scholar
• VERSCHRAAGEN M, KOKS CHW, SCHELLENS JHM et al.: P-glycoprotein system as a determinant of drug interactions: the case of digoxin–verapamil. Pharmacol. Res. (1999) 40(4):301-306.
   PubMed Web of Science ®Google Scholar
• MORDEL A, HALKIN H, ZULTY L et al.: Quinidine enhancers digitalis toxicity at therapeutic serum digoxin levels. Clin. Pharmacol. Ther. (1993) 53(4):457-462.
   PubMed Web of Science ®Google Scholar
• VERSTUYFT C, STRABACH S, El MORABET H et al.: Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin. Pharmacol. Ther. (2003) 73(1):51-60.
   PubMed Web of Science ®Google Scholar
• GRAMATTE T, OERTEL R: Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin. Pharmacol. Ther. (1999) 66(3):239-245
   PubMed Web of Science ®Google Scholar
• HSPAHN-LANGGUTH H, BAKTIR G, RADSCHUWEIT A et al.: P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. (1998) 36(1):16-24.
   PubMed Web of Science ®Google Scholar
• MALINGRE MM, BEIJNEN JH, ROSING H et al.: Co-administration of GF-120918 significantlyincreases the systemic exposure to oral paclitaxel in cancer patients. Br. J. Cancer (2001) 84(1):42-47.
   PubMed Web of Science ®Google Scholar
• FRACASSO PM, WESTERVELDT P, FEARS CA et al.: Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC-833 (valspodar), in refractory malignancies. J. Clin. Oncol. (2000) 18(5):1124-1134.
   PubMed Web of Science ®Google Scholar
• ADVANI R, FISHER GA, LUM BL et al.: A Phase I trial of doxorubicin, paclitaxel, and valspodar (PSC-833), a modulator of multidrug resistance. Clin. Cancer Res. (2001) 7(5):1221-1229.
   PubMed Web of Science ®Google Scholar
• SPARREBOOM A, PLANTING AS, JEWELL RC et al.: Clinical pharmacokinetics of doxorubicin in combination with GF-120918, a potent inhibitor of MDR1 P-glycoprotein. Anti-Cancer Drugs (1999) 10(8):719-728.
   PubMed Web of Science ®Google Scholar
• ACHIRA M, ITO K, SUZUKI H et al.: Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS Pharma Sci. (1999) 1(1):1-6.
   Google Scholar
• CHOO EF, LEAKE B, WANDEL C et al.: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. (2000) 28(6):655-660.
   PubMed Web of Science ®Google Scholar
• GREINER B, EICHELBAUM M, FRITZ P et al.: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. (1999) 104(2):147-153.
   PubMed Web of Science ®Google Scholar
• DURR D, STIEGER B, KULLAK-UBLICK GA et al.: St. John’s Wort induces intestinal glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmarcol. Ther. (2000) 68(6):598-604.
   PubMed Web of Science ®Google Scholar
• WESTPHAL K, WEINBRENNER A, ZSCHIESCHE M et al.: Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug–drug interaction. Clin. Pharmacol. Ther. (2000) 68(4):345-355.
   PubMed Web of Science ®Google Scholar
• MUCK W, MAI I, FRITSCHE L et al.: Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin. Pharmacol. Ther. (1999) 65(3):251-261.
   PubMed Web of Science ®Google Scholar
• SHITARA Y, ITOH T, SATO H et al.: Inhibition of transporter-mediated hepatic uptake as a mechanism for drug–drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther. (2003) 304(2):610-616.
   PubMed Web of Science ®Google Scholar
• REGAZZI MB, IACONA I, CAMPANA C et al.: Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. (1993) 25(4):2732-2734.
   PubMed Web of Science ®Google Scholar
• BACKMAN JT, KYRKLUND C, NEUVONEN PJ: Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmcol. Ther. (2002) 72(6):685-691.
   PubMed Web of Science ®Google Scholar
• SHITARA Y, HIRANO M, SATO H et al.: Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. (2004) 311(1):228-236.
   PubMed Web of Science ®Google Scholar
• KYRKLUND C, BACKMAN JT, NEUVONON M et al.: Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther. (2003) 73(6):538-544.
   PubMed Web of Science ®Google Scholar
• Pravachol® package insert. Bristol-Myers Squibb Company, New Jersey, USA (2004).
   Google Scholar
• HAMMAN MA, BRUCE MA, HAEHNER-DANIELS BD et al.: The effect of rifampin administration on the disposition of fexofenadine. Clin. Pharmacol. Ther. (2001) 69(3):114-121.
   PubMed Web of Science ®Google Scholar
• LIPPERT C, LING J, BROWN P et al.: Mass balance and pharmacokinetics of MDL16,455A in healthy male volunteers. Pharm. Res. (1999) 12:S390 (Abstract).
   Google Scholar
• CVETKOVIC M, LEAKE B, FROMM MF et al.: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. (1999) 27(1):866-871.
   PubMed Web of Science ®Google Scholar
• DRESSER GK, BAILEY DG, LEAKE BF et al.: Fruit Juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. (2002) 71(1):11-20.
   PubMed Web of Science ®Google Scholar
• SATOH H, YAMASHITA F, TSUJIMOTO M et al.: Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos. (2005) 33(4):518-523.
   PubMed Web of Science ®Google Scholar
• DRESSER GK, KIM RB, BAILEY DG: Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther. (2005) 77(3):170-177.
   PubMed Web of Science ®Google Scholar
• LEE CG, GOTTESMAN MM: HIV-1 protease inhibitors and the MDR1 multidrug transporter. J. Clin. Invest. (1998) 101(2):287-288.
   PubMed Web of Science ®Google Scholar
• GIBBS MA, THUMMEL KE, SHEN DD et al.: Inhibition of cytochrome P450 3A (CYP3A) in human intestinal and liver micromoses: comaprison of Ki values and impact of CYP3A5 expression. Drug Metab. Dispos. (1999) 27(2):180-187.
   PubMed Web of Science ®Google Scholar
• KHALIG Y, GALLICANO K, VENANCE S et al.: Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. (2000) 68(6):637-646.
   PubMed Web of Science ®Google Scholar
• HEBERT MF, ROBERTS JP, PRUEKSARITANONT T et al.: Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmcol. Ther. (1992) 52(5):453-457.
   PubMed Web of Science ®Google Scholar
• OLKKOLA KT, BACKMAN JT, NEUVONEN PJ: Midazolam should be avoided in patients receving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. (1994) 55(5):481-485.
   PubMed Web of Science ®Google Scholar
• BACKMAN JT, OLKKOLA KT, NEUVONEN PJ: Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Ther. (1996) 59(1):7-13.
   PubMed Web of Science ®Google Scholar
• POLLI JW, JARRETT JL, STUDENBERG SD et al.: Role of P-glycoprotein on CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. (1999) 16(8):1206-1212.
   PubMed Web of Science ®Google Scholar
• MAYER U, WAGENAAR E, DOROBEK B et al.: Full blockade of intestinal P-glycoprotein and extensive inhibition of blood–brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. (1997) 100(10):2430-2436.
   PubMed Web of Science ®Google Scholar
• SMIT JW, HUISMAN MT, VAN TELLINGEN O: Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. (1999) 104(10):1441-1447.
   PubMed Web of Science ®Google Scholar
• SCHINKEL AH, SMIT JJM, VAN TELLINGEN O et al.: Disruption of the mouse mdr 1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell (1994) 77(4):491-502.
   PubMed Web of Science ®Google Scholar
• JONKER JW, WAGENAAR F, MOL CA et al.: Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol. Cell Biol. (2001) 21(16):5471-5477.
   PubMed Web of Science ®Google Scholar
• BARZA M, WEINSTEIN L: Pharmacokinetics of the pencillins in man. Clin. Pharmacokinet. (1976) 1(4):297-308.
   PubMedGoogle Scholar
• SPINA SP, DILLON EC Jr : Effect of chronic probenecid therapy on cefazolin serum concentration. Ann. Pharmacother. (2003) 37(5):621-624.
   PubMed Web of Science ®Google Scholar
• CUNDY KC: Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. (1999) 36(2):127-143.
   PubMed Web of Science ®Google Scholar
• TSURUO T, ILDA H, TSUKAGOSHI S et al.: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. (1981) 41(5):1967-1972.
   PubMed Web of Science ®Google Scholar
• BOOTE DJ, DENNIS IF, TWENTYMAN PR et al.: Phase I study of etoposide with SDZ PSC-833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. (1996) 14(2):610-618.
   PubMed Web of Science ®Google Scholar
• CUI Y, KONIG J, BUCHHOLZ JK et al.: Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, permanently expressed in human and canine cells. Mol. Pharmacol. (1999) 55(5):929-937.
   PubMed Web of Science ®Google Scholar
• RAUTIO J, HUMPHREYS JE, WEBSTER LO et al.: In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab. Dispos. (2006) 34(5):786-792.
   PubMed Web of Science ®Google Scholar
• CUI Y, KONIG J, KEPPLER D: Vectorial transport by double-transfectedcells expressing the human uptake transporter SLC21A8 and apical export pump ABCC2. Mol. Pharmacol. (2001) 60(5):934-943.
   PubMed Web of Science ®Google Scholar
• ZHANG L, STRONG JM, QIU W et al.: Scientific perspectives on drug transporters and their role in drug interactions. Mol. Pharm. (2006) 3(1):62-69.
   PubMed Web of Science ®Google Scholar
• TAIPALENSUU J, TORNBLOM H, LINDBERG G et al.: Correlation of gene expression of ten drug efflux proteins of the ABC-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell molayers. J. Pharmacol. Exp. Ther. (2001) 299(1):164-170.
   PubMed Web of Science ®Google Scholar
• GOH L-B, SPEARS KJ, YAO D et al.: Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem. Pharmacol. (2005) 64(11):1569-1578.
   Google Scholar
• BENET LZ, CUMMINS CL, WU CY: Transporter–enzyme interactions: implications for predicting drug–drug interactions from in vitro data. Curr. Drug Metab. (2003) 4(5):393-398.
   PubMed Web of Science ®Google Scholar
• BENET LZ, CUMMINS CL, WU CY: Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm. (2004) 277(1-2):3-9.
   PubMed Web of Science ®Google Scholar
• LIN JH: Sense and nonsense in the prediction of drug–drug interaction. Curr. Drug Metab. (2000) 1(4):305-331.
   PubMed Web of Science ®Google Scholar
• ITO K, IWATSUBO T, KANAMITSU S et al.: Prediction of pharmacokinetic alterations caused by drug–drug interactions: metabolic interaction in the liver. Pharmacol. Rev. (1998) 50:387-411.
   PubMed Web of Science ®Google Scholar
• SASAKI M, SUZUKI H, ITO K, ABE T et al.: Transcellular transport of organic anions across a double-transfected Madin–Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2(MRP2/ABCC2). J. Biol. Chem. (2002) 277(8):6497-6503.
   PubMed Web of Science ®Google Scholar
• KOPPLOW K, LETSCHERT K, KONIG J et al.: Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol. Pharmacol. (2005) 68(4):1031-1038.
   PubMed Web of Science ®Google Scholar
• SHITARA Y, SATO H, SUGIYAMA Y: Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs. Ann. Rev. Pharmacol. Toxicol. (2003) 45:689-274.
   Web of Science ®Google Scholar
• TRAUNER M, BOYER IL: Bile salt transporters: molecular characterization, function and regulation. Physiol. Rev. (2002) 83(2):633-671.
   Web of Science ®Google Scholar
• KIPP H, PICHETSHOTE N, ARIAS IM: Transporters on demand: intracellular pools of canalicular ATP binding cassette transporters in rat liver. J. Biol. Chem. (2001) 276(10):7218-7224.
   PubMed Web of Science ®Google Scholar